Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company
|
EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Key word(s): Miscellaneous
Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company
The shares of SCHOTT Pharma AG & Co. KGaA (the “Company”; WKN A3ENQ5, ISIN DE000A3ENQ51), a global market leader for drug containment solutions and delivery systems, will be included in the SDAX for the first time as of December 1582023. Andreas Reisse, CEO of SCHOTT Pharma, said: “Following our successful IPO just a little over two months ago, SCHOTT Pharma’s inclusion in the SDAX shows that investors have confidence in our business model and see the potential of our company. We look forward to building on this milestone, benefiting from increased visibility in the global capital markets, and pursuing our strategy.” As part of the 160 most important shares listed on the Frankfurt stock exchange, the SDAX index comprises the 70 largest and most liquid companies following the DAX and MDAX in terms of market capitalization. The main criterion for the weighting of SDAX shares is market capitalization based on free float (minimum of 10%), which is around 23% for SCHOTT Pharma. The company went public on September 28 this year on the Frankfurt Stock Exchange, marking the largest German IPO of 2023. Dr. Almuth Steinkühler, CFO of SCHOTT Pharma, said: “We saw a fantastic initial jump of the share price following our successful IPO, and we are delighted to now enter the SDAX as we remain well on track to meet our growth targets.” The company plans to announce its full year financials at a press conference on January 26, 2024.
About SCHOTT Pharma SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is fully owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 821 million in the fiscal year 2022.
Jasko Terzic Joana Kornblum Simon Steiner Christopher Raad
06.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1789917 |
| End of News | EQS News Service |
|
|
1789917 06.12.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.